Neurotech International Ltd. · ASX:NTI
Neurotech International — Shareholder Meeting (November 2017)
12 slides from Neurotech International's shareholder meeting presentation, Nov 23, 2017
Slide 1: Improving the lives of people with neurological conditions
For personal use only Improving the lives of people with neurological conditions Annual General Meeting Neurotech International Limited (ASX: NTI) | November 2017
Slide 2: Neurotech Overview
Neurotech Overview For personal use only ✓ Medical device company, focussed on the development & commercialisation of regulated medical solutions for diagnosis & treatment of neurological disorders ✓ Flagship device Mente Autism provides home-based neurofeedback therapy to children on the autism spe
Slide 3: Preliminary US Clinical Trial Outcomes
Preliminary US Clinical Trial Outcomes For personal use only Preliminary results from US clinical study “…one of the most exciting investigations this year. The changes observed in autistic children after a 12-week clinical trial are outstanding with many of the children with autism scoring in a nor
Slide 4: Parents' Testimonials
Parents’ Testimonials For personal use only “… he’s drawn in the eyes, mouth and nose autonomously…” “… do you like the headband?” “… yes I do… Men-te.” More testimonials at: www.mentetech.com/mente-autism/testimonials 4
Slide 5: Distribution
Distribution For personal use only • The Mente Autism device is being distributed through a growing network of partners around the world • Our initial focus in the European market, and have gained significant distributor momentum with five new agreements signed since our IPO in November 2016, predom
Slide 6: Case Study: German Market Entry Strategy
Case Study: German Market Entry Strategy For personal use only • Distributor agreement signed in April 2017 with VDT Psychologie Medizinvertrieb • Three-step approach to creating structure to develop a successful market in Germany: 1. Appoint distribution partner (done) 2. Build medical professional
Slide 7: New Mente Autism Distribution Partners
New Mente Autism Distribution Partners For personal use only • Marketing & distribution • Exclusive marketing & • Marketing & distribution • Marketing & distribution • Exclusive marketing & partner in Australia distribution partner in Saudi partner in Germany & partner in Greece & Cyprus distributio
Slide 8: US Market and FDA approval
US Market and FDA approval For personal use only • The United States remains an important target market for the Mente Autism device • We are starting to put the foundations in place to pursue approval from the US Food and Drug Administration (FDA) and our dealings with the FDA have so far been posit
Slide 9: Key Achievements & Next Milestones
Key Achievements & Next Milestones For personal use only Achievements Looking Forward… The Company has made substantial achievements in the We are focussed on continuing to let science do the space of less than 12 months: talking, and bringing Mente Autism to the parents and children who need it ✓ N
Slide 10: Contact Details
Contact Details For personal use only Company Investor / Media Relations Wolfgang Storf, Chief Executive Officer Matthew Wright [email protected] [email protected] Neurotech International Ltd NWR Communications Level 14, 191 St Georges Terrace Level 6, 350 Collins St Perth Western
Slide 11: Disclaimer
Disclaimer For personal use only This presentation contains forward looking statements that involve risks and uncertainties. These forward looking statements are not guarantees of Neurotech’s future performance and involved a number of risks and uncertainties that may cause actual results to differ
Slide 12: For personal use only
For personal use only www.neurotechinternational.com www.mentetech.com
Neurotech International — Shareholder Meeting (November 2017) on 6ix